G. Kees Hovingh

Research interests

Publications

• Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

  New England Journal of Medicine · 2025 · 10.1056/nejmoa2501006

• Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

  The Lancet · 2024 · 10.1016/s0140-6736(24)00469-0

• Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2313917

• Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

  Nature Medicine · 2024 · 10.1038/s41591-024-02996-7

• Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2306963

• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2307563

• Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

  The Lancet · 2021 · 10.1016/s0140-6736(21)01122-3

• IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00520-1

• EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study

  European Journal of Preventive Cardiology · 2020 · 10.1093/eurjpc/zwaa047

• Evinacumab for Homozygous Familial Hypercholesterolemia

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2004215

• Clinical Genetic Testing for Familial Hypercholesterolemia

  Journal of the American College of Cardiology · 2018 · 10.1016/j.jacc.2018.05.044

• ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia

  New England Journal of Medicine · 2017 · 10.1056/nejmc1705994

• Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus

  JAMA · 2015 · 10.1001/jama.2015.1206

• Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

  Archives of Medical Science · 2015 · 10.5114/aoms.2015.49807

• Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

  European Heart Journal · 2015 · https://doi.org/10.1093/eurheartj/ehv043

• Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

  European Heart Journal · 2015 · https://doi.org/10.1093/eurheartj/ehv043

• ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

  European Heart Journal · 2015 · 10.1093/eurheartj/ehv370

• Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction

  Nature · 2014 · 10.1038/nature13917

• HDL and cardiovascular disease

  The Lancet · 2014 · 10.1016/s0140-6736(14)61217-4

• PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

  The Lancet · 2014 · 10.1016/s0140-6736(14)61399-4

• Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

  The Lancet · 2014 · 10.1016/s0140-6736(14)61374-x

• Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome

  European Heart Journal · 2014 · 10.1093/eurheartj/ehu058

• Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

  European Heart Journal · 2014 · https://doi.org/10.1093/eurheartj/ehu274

• The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

  The Lancet Diabetes & Endocrinology · 2013 · 10.1016/s2213-8587(13)70191-8

• The PCSK9 decade

  Journal of Lipid Research · 2012 · 10.1194/jlr.r026658

Current projects

No projects listed.